“The New Stroke Treatment That’s Changing Lives”
Sunday Night (Australia), March 29, 2015
On March 29, 2015 the television news program “Sunday Night” in Australia aired a national news feature story about INR’s perispinal etanercept stroke treatment. The story was entitled “The New Stroke Treatment That’s Changing Lives”, and it is accessible online at this link:
In the television feature, the clinical results of two patients treated at the INR by INR Los Angeles medical director Nancy Kim M.D., are depicted. The story was filmed both in Los Angeles at the time of treatment and in Australia, after each of the patients returned home.
Issue 10, volume 4, Supplement of Alzheimer’s and Dementia: Journal of the Alzheimer’s Association, Session 04-11-02, P273, entitled “The Safety and Tolerability of etanercept in Alzheimer’s disease (STEADI-09): A Phase II Double Blind Randomised Placebo Controlled Trial”, principal investigator Clive Holmes MD, University of Southampton, Southampton, United Kingdom, contains the first double-blind, randomized, placebo-controlled data supporting the therapeutic efficacy of etanercept for treatment of Alzheimer’s disease. The abstract of this study (full-text here) published in this issue in July 2014. The abstract concludes:
“This study shows good tolerability and safety of Etanercept in the subjects with Alzheimer’s Disease. This study is also supportive of beneficial cognitive, behavior and activities of daily living in subjects taking subcutaneous Etanercept.”
A 2008 article in BBC News had previously discussed the favorable results of etanercept for treatment of Alzheimer’s disease in a study whose lead author was Edward Tobinick M.D. The article reported at the time that Clive Holmes MD was interested in taking on further research utilizing this treatment approach.
May 10, 2014
Two scientists from the UCLA Department of Neurology have published a new research article entitled “Intracerebral hemorrhage in mouse models: therapeutic interventions and functional recovery“, Metab Brain Dis. 2014 epub May 10.
The authors recognize intracerebral hemorrhage as a subtype of focal stroke and the most common form of brain hemorrhage. The authors explain,
“With direct blood extravasation into brain, secondary inflammation is a substantial feature. Drugs which reduce neuroinflammation enhance functional recovery. Lei and colleagues targeted tumor necrosis factor alpha (TNF-alpha), a cytokine that is secreted by the microglia in response to injury and acts as a prime neuroinflammatory mediator causing progressive damage. A single dose of TNF-alpha antibody … showed evidence of reduced neuroinflammation and improved functional deficit….”
For further information regarding the INR, please see the following sources, accessible by clicking on the links below: